Biosimilar Medicines

AxSpA patients were recently represented at a biosimilar medicines patient leader workshop organised by Medicines for Europe. Rene Anour, Chair of the Biosimilar Medicines Working group at the European Medicines Agency (EMA) and Sarah Ikenberry from the US Food and Drug Administration (FDA) (pictured left) heard from ASIF’s Jo Lowe as she shared her thoughts on what people living with axSpA need to know about biosimilar medications. Both Rene and Sarah play a key role in providing patients with accurate and helpful information about biosimilar treatments. 

About 20 patients and patient representatives from different disease areas attended the workshop, along with biosimilar manufactures. They each gave their view on what the most important considerations are when patient information about biosimilar medicines is put together. Opportunities like these are invaluable for ensuring the patient voice is heard by those creating drug-related information for patients. The event took place in Amsterdam on 17 April.

Following the workshop, Jo attended the annual Biosimilar Medicines Conference.  The event addressed the main challenges in increasing patient access to biosimilar treatments, including building a European biosimilar strategy and how the impact of new policies can be measured.  Sessions were also held on planning for future treatment needs and regulatory policy.

Other NEWS